1-MQ / 1-Methylquinolinium
Revs up the metabolic engine of adipocytes.
Oral; SC injection (short bursts) — 50–100 mg daily for 4–6 weeks under supervision; oral or by injection per physician protocol
What It Is
1-MQ (1-Methylquinolinium) is a small molecule, not a peptide, but is often included in peptide discussions for its unique action as an NNMT inhibitor. It blocks nicotinamide N-methyltransferase, an enzyme in fat cells that consumes NAD+ and slows metabolism.
Mechanism
By inhibiting NNMT, 1-MQ can raise intracellular NAD levels and remove a "brake" on fat burning. In preclinical studies, NNMT inhibition led to increased energy expenditure, reduced fat mass, and improved glucose tolerance in obese mice. Essentially, 1-MQ revs up the metabolic engine of adipocytes, making them burn more calories. This makes it a promising anti-obesity and body-composition agent.
How Dr. Emer Uses It
In practice, 1-MQ is still experimental; some wellness physicians use it in compounding form for weight loss plateaus or "stubborn fat" cases. It might be given orally or by injection in short bursts (e.g. 50–100 mg daily for 4–6 weeks) under supervision. Dr. Emer might consider 1-MQ for a patient who, despite diet/exercise and maybe GLP-1 therapy, still has a sluggish metabolism or visceral fat that's not budging — particularly if that patient's labs show low NAD+ or high NNMT activity.
Key Benefits
- ✓Inhibits NNMT to raise intracellular NAD levels and remove "brake" on fat burning
- ✓Increases energy expenditure and reduces fat mass in preclinical models
- ✓Improves glucose tolerance — complementary metabolic benefit
- ✓Targets adipocyte metabolism directly to increase caloric burn
- ✓Useful for weight loss plateaus or stubborn fat refractory to GLP-1 therapy
- ✓Complements MOTS-c and NAD+ by addressing different angles of metabolic dysfunction
Pairs Well With
Used In Programs
Safety & Considerations
While promising, 1-MQ's human safety is not fully known. Potential side effects could include mild hepatotoxicity (if 1-MQ accumulates substrates elsewhere) or blood pressure changes (if catecholamine metabolism is affected). So far, users have anecdotally reported increased energy and mild appetite suppression, with rare headaches. EmerGPT would flag that alternatives for similar effect include niacin or other NAD-boosting strategies; 1-MQ is reserved for targeted cases after weighing R/B/A.
Begin Your RECODEX™ Protocol
All peptide therapies are prescribed under direct medical supervision.
Book a Consultation
